AI-Based Cardiac Analysis Using 12-Lead and 1-Lead ECG
Prospective Observational Comparative Pilot Study to Evaluate Performance of an AI-based Cardiac Disease Analysis Algorithm Using Standard 12-lead ECG and Single-lead ECG Data
This pilot study is designed to evaluate the clinical performance and utility of the SmartECG-EF software in patients undergoing evaluations at Inha University Hospital. The primary objective is to assess how effectively the device assists clinicians in evaluating cardiac function and related clinical parameters. The study will prospectively enroll eligible participants to gather real-world clinical data, contributing to enhanced diagnostic accuracy and patient management.
調査の概要
詳細な説明
This is a prospective, single-center pilot study conducted at Inha University Hospital to evaluate the clinical performance and feasibility of the SmartECG-EF software. Eligible participants will undergo standard clinical evaluations alongside the investigational device assessment. The study aims to investigate the diagnostic utility and operational workflow of integrating the software into routine clinical practice. Data regarding clinical parameters, primary and secondary outcome measures, and any device-related adverse events will be systematically collected and analyzed to assess safety and efficacy.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Yongsoo Baek, M.D., Ph.D.
- 電話番号：+82-32-890-2200
- メール：existsoo@inha.ac.kr
研究場所
-
-
Incheon
-
Incheon、Incheon、韓国、22332
- 募集
- Inha University Hospital
-
コンタクト：
- Yongsoo Baek, M.D., Ph.D.
- 電話番号：+82-32-890-2200
- メール：existsoo@inha.ac.kr
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients visiting Inha University Hospital who undergo standard 12-lead and additional 1-lead ECG evaluations for cardiac assessment.
説明
Inclusion Criteria:
- Written informed consent provided voluntarily by the subject
- Age ≥ 19 years
- Patients who undergo standard 12-lead ECG measurement during the study period
- Subjects with sinus rhythm on ECG at the time of examination
- Subjects available for additional 1-lead ECG measurement during the same visit
Exclusion Criteria:
- Subjects deemed inappropriate or unlikely to comply with the study requirements by the investigator
- Patients with atrial fibrillation or atrial flutter on ECG at the time of examination
- Patients with pacing rhythm due to a pacemaker
- Subjects with severe tremor, uncooperativity, or skin conditions that make 1-lead ECG measurement difficult
- Subjects whose additional study measurements would delay standard medical care due to a critical medical condition
- Withdrawal of consent or refusal to agree to personal information usage
- ECG with sub-standard quality (unanalyzable noise, lead disconnection, etc.; note: unanalyzable rate evaluation can be recorded separately)
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：COHORT
- 時間の展望：PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
SmartECG-EF Evaluation Group
Patients undergoing prospective evaluation using the SmartECG-EF software for cardiac function assessment and ECG-based parameter analysis at Inha University Hospital. |
The SmartECG-EF software is used to analyze 12-lead and 1-lead electrocardiogram (ECG) data to evaluate cardiac function, including left ventricular systolic dysfunction (LVSD), heart failure indicators, and related arrhythmic parameters. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Correlation and Agreement between 12-Lead and 1-Lead AI Scores
時間枠：Day 1
|
To evaluate the correlation (using Pearson or Spearman correlation coefficients), agreement (ICC using absolute agreement, two-way random model), and Bland-Altman analysis (mean difference and 95% limits of agreement) between 12-lead and 1-lead based AI scores. |
Day 1
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Area Under the ROC Curve (AUC-ROC) of AI scores
時間枠：Baseline
|
To assess the AUC-ROC of 1-lead and 12-lead based AI results against disease-specific reference standards, including heart failure, left ventricular systolic dysfunction (LVSD), and arrhythmic parameters. |
Baseline
|
|
Sensitivity and Specificity of AI scores
時間枠：baseline
|
To assess sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 1-lead and 12-lead based AI results against disease-specific reference standards, including heart failure, left ventricular systolic dysfunction (LVSD), and arrhythmic parameters. |
baseline
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2026-03-034-001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
A specific plan for sharing individual participant data has not yet been finalized as this is a pilot study. Data sharing will be evaluated upon reasonable request and in accordance with institutional guidelines and IRB approvals.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。